• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
The PUMBA Gazette - january 2011

The PUMBA Gazette - january 2011






Total Views
Views on SlideShare
Embed Views



0 Embeds 0

No embeds


Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

    The PUMBA Gazette - january 2011 The PUMBA Gazette - january 2011 Document Transcript

    • 0
    • The Editorial ContentsHippocrates himself would, today, be surprised at theastonishing speed with which Medicine has • Cover Story 2revolutionized itself. Gone are the days when diseases -- Cancer Drugs Available...were generalized and treatments meted out were notspecific. We have entered an era where technology has But Unavailable...the power to pinpoint the cause of diseases at thegenetic level and then can proceed to recommend • Article 4therapies that would specifically repair these aberrations.The Human Genome Project has unraveled the -- “Onco”ntrolmysterious ways in which the genes function and madeway for extensive research related to it.Cancer is no longer considered a disease linked only to • ‘Innov’Era 5environmental factors. Scientists have discovered that -- ‘Can’cer Treatment: A Reality!!!some forms of the disease like Breast cancer & Ovariancancer can occur due to genetic factors as well. Due tothis interdependence, Scientists are looking at therapies • The Industry Buzz 6that will work at the genetic level like -- NoMoreSulidePharmacogenomics, Gene Therapy, Stem Cell Therapy,Antisense Therapy, etc. With this emerging new arena in -- Biocon Suffers a Setback as Oralsight we have thus dedicated this issue of The PUMBAGazette to Oncology and its prospective treatments. Insulin Trials FailTo broaden our horizons on this topic we personallyinterviewed Oncologists in Pune and got their perspective • Candid Talk 7on the reasons of unavailability of Cancer drugs and whatthe pharmaceutical companies are doing to remedy this -- An Interview with Mr. Manishissue. PungaliyaTaking the theme further we interviewed Mr. ManishPungaliya, Director Ayugen Biosciences in order tounderstand the scope of Pharmacogenomics in Cancer • PUMBA News 8Treatment.Also included is an article on the current Cancer -- Dhruv ‘11treatments that are available to patients. -- Nostalgia 2011The periodical for this edition elaborates on the host ofalternative cancer therapies that are replacing the -- National Seminar 2011conventional treatments that were once thought asirreplaceable. -- YuktiThe BT news section focuses on the ban on Nimesulideand phenylpropylamine drugs in India and on the hugesetback to the eagerly awaited oral insulin by Biocon.We wind up the edition with PUMBA News bringing youall the happenings that have taken place here in PUMBA.“Reading maketh a full man; conference a readyman; and writing an exact man.” - Francis BaconSincerely Yours,Editor-in-Chief:Chime Y. Mishra (MBA Biotechnology - SEM IV)The PUMBA Gazette Team(The detailed project report shall be provided on enquiry.Kindly send in your enquiries atthepumbagazette@gmail.com) 1
    • Cover StoryCANCER DRUGS AVAILABLE… kinds of drugs yet or if they are being developed the long duration between the approvals and the commercial BUT UNAVAILABLE… availability is the negating factor as many lives are lost The Oncology market has grown at more than double due to lack of treatment in this duration. Some also findthe rate of global pharmaceuticals, with a CAGR of 8.39% one of the reasons to be the withdrawal of the drugsduring 2004–’08. But does the ultimate cause of any drugdevelopment actually being achieved? Even with thisincrease in the available drugs as well as reported cases,are these drugs reaching the final consumer i.e., thePatient? It is a rarely asked question but an importantone in analyzing the role of pharma companies incontributing to the oncology treatments. It was the mainobjective of this month’s survey by the PUMBA Gazetteteam i.e., to assess the availability of cancer drugs topatients in all terms: drug development, market capture,cost factor, lack of quick approvals and withdrawals.The oncologists in the Pune region were interviewed togather the information on the availability of drugs, thereason for this non availability and chiefly the rolepharma companies are playing in making these drugs which were found effective for disease curing owing toavailable to patients. the potential side-effects. E.g. Mylotarg of Wyeth which was approved under the accelerated approval program ofAVAILABILITY OF DRUGS FDA used for the treatment of relapsed acute myeloidThe most incident cancers in Pune were found to be leukaemia (AML). It has been withdrawn owing to lack ofbreast, cervical, oral and lung cancers with the most any additional clinical benefit and increased toxicity whenrecovered one to be breast cancer due to ample drugs administered with chemotherapy. Another of the main reasons was also found to be that a few drugs have not yet been approved in India depriving Indian patients of the benefits. COST FACTOR According to the survey of the PUMBA Gazette team, in Pune region, almost 70% of the oncologists think that the drug price being high affects the percentage of patients recovering from cancer (recovery percentage). The oncologists have almost 80 % of the patients visiting them for treatment from lower and middle economic strata (35% Low, 45% Middle). With this high share of economically not well-to-do patients with not much of income to spend in the costly cancer treatment, many patients die untreated or have to withdraw in the middle, i.e., less recovery percentage. A study proves that the newly developed drugs areavailable on the basis of an analysis on the availability of costing even higher than the already available drugs.drugs for certain types of cancer. Drugs are ample for Some of the newly-approved brands cost USD 150-500KLymphoma too. However, the drugs are found to be just per life year gained.enough for the treatment of lung cancer, prostate cancer, “...the addition of ixabepilone to capecitabineovarian cancer, colorectal cancer and leukaemia. (Xeloda) adds about $31,000 to the overall medicalAccording to oncologists the drugs are scarcely available costs of metastatic breast cancer while providingfor treatment of pancreatic cancer. about 1 more month of ‘quality-adjusted’ survival”. Journal of Clinical Oncology, May 1, 2009.REASONS FOR NONAVAILABILITYMost of the doctors think high drug costs to be the chief This and many more studies suggest that the drugs’ reachreason for unavailability of the drugs followed by non to the economically backwards is reducing. Ironically,development and lack of approvals and trials duration. with the development of newer drugs this class of societyThere are many indications for which we don’t have any 2
    • is getting even more deprived of treatment due to high less than $75000/year before its withdrawal. Amgen hascosts. a price cap on Vectibix™ in USA since 2006 at $4000/ dose, approximately 20% less than the other antibody onWHY THE COSTS ARE HIGH? the market (BMS’s Erbitux®) for metastatic colorectalAlmost 50% of doctors directly blame the high costs of cancer. Another of these initiatives are the Pay-for-drugs on the pharma companies saying that the motive Performance programs, e.g., in Britain, Johnson &behind such high prices is just high profit as they are Johnson offered a money-back guarantee if Velcadeultimately doing a business and they are in business to failed to reduce tumours by at least 25%. However,add to their bottom line inconsiderate to the fact that Indians are still waiting for any such price cap initiatives.these drugs are necessities which need to reach more . The accelerated drugs approvals have been beneficialand more people. They also think that the unavailability but a few people debate that whether acceleratedof any alternative also adds as an advantage to the approvals are improved access to therapeuticcompanies’ high profit motive until any competition breakthroughs or early release of unsafe and ineffectivecomes up. An equal number of respondents do not blame drugs? This question is going to remain as we haveit on the companies directly but the need to recover the examples on both the facets. Mylotarg was approved inhuge costs companies have put into the research and 2000 came out to be ineffective and withdrawn in Junedevelopment of these drugs as a reason behind the high 2010 and Cetuximab was approved under acceleratedprices. approval program in March 2004 for the treatment of patients with metastatic colorectal cancer had till yetARE COMPANIES DOING ANYTHING? been proved good with a few non fatal side effects only.A 29% of the oncologists’ perception is that the pharma There are several Patient advocacy groups also who assistcompanies are just profit oriented and are not playing people in accessing the drugs through expanded accessany role in the drug reach increase. But a good 71% think programs and compassionate use programs which allowthat even being profit oriented some initiatives are being patients to receive investigational drugs earlier thantaken by the companies so as to make the drugs reach phase III of the clinical trial process i.e., earlier than themore and more patients. They have rated Pfizer, BMS, FDA approval. When patient advocacy groups learnedRoche, Cipla and Novartis to be a few companies active in that Herceptin was showing promise in clinical trials, theydoing so along with Intas Pharmaceuticals, EliLilly, Dr. pressured the manufacturer, Genentech, to provide theReddy’s Laboratories and Innova Healthcare. Thirty drug early to certain patients.percent of oncologists say that the companies are givingfree samples to the patients so as to make it reach the WHAT SHOULD COMPANIES DO?poor. E.g., Novartis’ Gleevec®/Glivec® have been Many doctors suggest that the companies should focusprovided free to the needy patients in India through the more on research and development and the multinationals should have their research centres in India as the cost of drug development is found to be lesser in India. The trials should be on larger scale involving more and more people. The costing should be caps based done on the basis of class and economic conditions of patients being served. The rural market should be targeted as a majority of population stays there and the facilities should be provided to them not only getting the companies reach more and more patients but also a good-will creation in a larger mass. Many people lack awareness so awareness programs could be a major benefit to both the sides. Another way to reduce costs is through licensing and supply deals across countries and such collaborations which will finally reduce the costs pressure on the patients. The parallel drug applications i.e., a single drug to be applicable to other indicationsGlivec International Patient Assistance Program (GIPAP). could also be a good way to increase availability, soPatient friendly company policies, reduced costs and research should be directed in these directions as well.accelerated approvals are few other initiatives by thecompanies. Generics are a very good advantage for the Compiled By:patients as they are the cheaper substitutes to their Richa Vijayvargiya, Shomali Naranje (MBA-BT SEM IV)branded counterparts with the similar affectivity. A few Apoorva Joshi, Ektaa Sharma, Neha Shedge, Gurudeep S. Dodmani, Vinay Pantulwar (MBA-BT SEM II)companies are also involved in inducing voluntary pricecaps on their drugs like Genentech had a price cap onAvastin at $55000/ year for households having income 3
    • Article“ONCO”NTROL Cancer vaccines represent an emerging type of biological Cancer vaccines are medicines that belong to a class of therapy that is still mostly experimental. Many clinicalsubstances known as biological response modifiers. trials are underway to test vaccines as potentialBiological response modifiers work by stimulating or treatments for a wide variety of cancer types.restoring the immune system’s ability to fight infectionsand diseases. There are two broad types of cancervaccines: * Preventive (or prophylactic) vaccines, which areintended to prevent cancer from developing in healthypeople. * Treatment (or therapeutic) vaccines, which areintended to treat an existing cancer by strengthening thebody’s natural defenses against the cancer.Active Clinical Trials of Cancer Treatment Vaccines by In one early-stage study, 18 of 20 patients who wereType of Cancer: vaccinated against non-Hodgkins lymphoma stayed in  Bladder Cancer remission for an average of four year. The vaccine used in  Brain Tumors this study contained a protein specific to each patient’s  Breast Cancer tumor cells (that is, each patient was given an autologous  Cervical Cancer vaccine) as well as two other substances to help boost  Hodgkin Lymphoma the immune response. A large, randomized, phase III trial  Kidney Cancer of this vaccine is now under way.  Melanoma  Multiple Myeloma From the market perspective, there are going to be  Leukemia multiple launches of vaccines between 2010 and 2013-  Lung Cancer 14, which would substantially increase the market size  Non-Hodgkin Lymphoma and growth. The cost of three complete dose courses of  Pancreatic Cancer the vaccines ranges approximately from $380 to $400.  Prostate Cancer The cancer vaccines developmental pipeline is strong  Solid Tumors with about 239 products in various phases of clinical development including 21 molecules in Phase III. TheActive Clinical Trials of Cancer Preventive Vaccines by Phase III pipeline activity is strong. It mainly consists ofType of Cancer: clinical studies involving antigen/adjuvant vaccines  Cervical Cancer regimen. The Phase III pipeline also contains some novel  Solid Tumors therapeutic vaccines. These options are also present inWorldwide, there is the potential to prevent 1.8 million the Phase II stage pipeline. With all these factors, it iscases of cancer (18%) each year by fighting infections. likely that the options in the pipeline will cause aThe proportion is even larger in the third world, where an dramatic change in the market in the near future and theestimated one in four cancers is linked to infection. market activity will primarily be dominated by theThe U.S. Food and Drug Administration (FDA) has molecules in the Phase II and Phase I pipeline.approved two vaccines, Gardasil® and Cervarix®, that The questions that need to be answered via research:protect against infection by the two types of HumanPapilloma Virus—types 16 and 18—that cause  Whether vaccines will be more effective whenapproximately 70 percent of all cases of cervical cancer given in combination with other forms of cancerworldwide. At least 17 other types of HPV are responsible therapyfor the remaining 30 percent of cervical cancer cases.  Whether the vaccine should be administeredHPV types 16 and/or 18 also cause some vaginal, vulvar, before chemotherapy, during chemotherapy oranal, penile, and oro-pharyngeal cancers. Therefore, after the course is completed.researchers must develop new vaccines that are able to  For therapeutic vaccines, the question is at whichprevent infections by all HPV types that can cause this stage should the vaccination be given?disease.  Whether vaccines can be used in case of cancers in multiple tissues?In April 2010, the FDA approved the first cancertreatment vaccine. This vaccine, sipuleucel-T (Provenge®, Compiled by:manufactured by Dendreon), is approved for use in some Shalet M. Koshy (MBA Biotechnology SEM IV)men with metastatic prostate cancer. Anjali Joshi (MBA Biotechnology SEM II) 4
    • ‘Innov’Era‘CAN’CER TREATMENT: A REALITY!!! and the general population. This presents a sizeable market opportunity. Research is being conducted in bothIn India, cancer is a silent crisis. It goes largely ovarian cancer and prostate cancer, which could haveunreported, and elicits little of the attention it deserves wide-market implications. Specifically, companies arefrom health authorities preoccupied with other pressing looking to validate new biomarkers in order to createhealth problems. Efforts at prevention and early more accurate tests.detection are extremely limited, as are diagnostic andtreatment services. Cancer survival rates in India are Apart from commonly used chemotherapy, hormonalexceptionally poor. Lack of awareness, stigma, and therapy and radiotherapy, few therapies like stem cellreliance on traditional healers mean most people do not transplantation, electromagnetic radiation therapy,seek medical help in time. Also, there is a common dendritic cell (antigen presenting cells) based vaccines,perception that cancer is transmissible, which leads to antisense therapy etc. have emerged as novel ways topatients being shunned by family and friends and inhibits treat cancer. As the name suggests, stem cellpeople from accessing screening or acknowledging early transplantation is transplantation of multipotentsymptoms. More than two third of cancer patients are hematopoietic stem cells or blood, often derived fromfirst seen with late stage disease, which has a poor bone marrow, umbilical cord blood or hemopoietic stemprognosis and is long, difficult and costly to treat. cells derived from a placenta into the patient as part of the therapy.Despite public policy measures to prevent cancer, such astobacco control and vaccination against HPV (Human In electromagnetic radiotherapy, low power, non-Papilloma Virus), cancer is sure to remain a significant ionizing, non thermal, radio or sub-radio frequencypublic health problem throughout the 21st century. The electromagnetic waves are produced which are helpful indemographic shift towards an ageing population and the treating the cancer.usage of high–tech modern medicine throughout theemerging economies of Asia and Africa will lead to the A dendritic cell based cancer vaccine induces strongexpansion of the market for cancer diagnostics globally. anticancer immunity by its potent immune-inducing abilities. It is a new paradigm in cancer treatment whichEarly diagnosis of cancer is essential to determine the induces not only strong anti-tumour immunity but alsotreatment regime. Computerized tomography, positron immune memory to prevent tumour recurrence oremission tomography, magnetic resonance imaging and metastasis. In this vaccine a live attenuated virus is usedultrasound imaging are some of the techniques used for which infects both healthy cells and tumour cells but itcancer detection. However these techniques are selectively replicates in tumour cells resulting in killingexpensive, require lab facilities and highly trained tumour cells and leaving healthy cells unaffected. It alsotechnicians, they are time consuming and cannot be results in production of antigens which induces tumourtaken into the field. Nanotechnology is one of the recent specific immune response, resulting in identifying andtechnologies used for cancer diagnosis. Nanotechnology destroying tumour cells systematically.is in a unique position to produce a new generation ofearly cancer detection techniques with higher sensitivity Antisense therapy has emerged as an exciting andand delivery of the drug to the target site. promising strategy for cancer therapy which works at the genetic level to prevent mutated or overactive genes byThe latest Technologies in Oncology Diagnostics range directing the synthesis of proteins that are causingfrom body imaging and cytology to molecular diagnostics cancer. They are differentand pharmacogenomics. The imaging techniques involve from conventional drugsMagnetic Resonance Imaging (MRI), X-ray, Computed as these are designed toTomography (CT), Ultrasound, Positron Emission interact with proteinTomography (PET), Single Photon Emission Computed molecules after they areTomography (SPECT) and Flow Cytometry. Similarly, the produced. Antisensemolecular diagnostics include Fluorescence In-Situ drugs have a moreHybridization (FISH), Polymerase Chain Reaction (PCR), selective action, and they have the potential to be moreHPV testing, Immunoassays & Biomarkers, Microarrays effective and less toxic than conventional drugs.and Comparative Genomic Hybridization (CGH).Molecular diagnostics and biomarkers are the key drivers Compiled by:of the oncology diagnostics market. Virtual colonoscopy, Hitesh Patil (MBA-BT SEM IV)using CT scans to build a picture of the colon, is becoming Neha Shedge & Seema Pawar (MBA-BT SEM II)an increasingly accepted alternative to invasivecolonoscopy for colorectal screening in high risk groups 5
    • The Industry BuzzNOMORESULIDE… Paracetamol and Ibuprofen were trying to get the drug banned because of the higher revenues it generated andIt seems that the Drug Technical Advisory Board of India it had nothing to do with the adverse effects it caused.has pulled its socks and rolled its sleeves once again. It However the test results as well as the reports from thehas finally decided to impose ban on the market always pointed that the problems posed arecommercialization two very controversial drugs being serious and need attention.sold in Indian market namely NIMESULIDE and PHENYLPROPYLAMINE (widely known as PPA). The move comes BIOCON SUFFERS A SETBACK AS ORALafter the debate that has lasted for a decade. The debatewas whether to ban Nimesulide in India or not. INSULIN TRIALS FAIL...The Nimesulide drug has already been banned in the Biocon suffered a serious setback this month when thedeveloped countries like Britain, Canada, Sweden, results of the clinical trials on the much awaited oralDenmark, New Zealand, Japan and many more. In USA insulin drug failed. The clinical trials on the drug failed tothe drug was not even filed for marketing. The main meet the primary goals.reason behind the ban imposed on the drug is the severeliver damage it causes. It was marketed in India despite of The drug is named as IN-105 by the company and hadbeing banned in the developed countries. cleared the Phase II of the clinical trials. The drug in clinical trials has to prove the efficacy test to reach the very important phase III. In the human clinical trials of IN- 105, it was supposed to lower the level of glycated haemoglobin by 0.7% however it failed to lower the levels as compared to placebo. In this case the effects on placebo were higher than expected by the researchers. The company said that they had not considered certain facts about the placebo and the assumptions proved to be wrong. However the company claims to have collected enough data to show that the results are positive and the research is on right track. The Biotech giant now has extended its arms to the global partnerships for the further research on theAlong with Nimesulide, Phenyl Propylamine, Cisapride molecule. The company plans to enter into globalare the other two drugs which DTAB has banned in India. partnerships and thus conduct more research and morePPA is the drug used in popular brands like D’cold, Vicks clinical trials. The company is highly optimistic about theAction 500 often prescribed for cold and cough remedies. output of the research studies and the clinical trialPPA was reported to be the reason of stroke in many report.young women. Whereas Cisapride prescribed to increasethe gastric motility in the upper GIT was reported to This drug and molecule being one of the most promisingcause serious heart related problem such as disturbed and the emerging market has given a lot of hopes to therhythms of heart beats. company as well as the Indian Biotechnology. It will be interesting to see how the molecule, on which Biocon hasThe Nimesulide tablet holds the market of Rs. 2710 been researching since around 2001, fares in comingCrores in Rs. 50000 Indian Pharma Market. According to days.the Drug Controller the drug should have been banned inIndia before 10 years ago but were not banned. Compiled by: Sumantsinh Girase (MBA Biotechnology SEM IV)Previously, two more drugs were banned in India. Thosewere Rosiglitazone which is an anti diabetes drug and theother one is Sibutramine. These were banned in India inthe month of November.In the defence, the manufacturers and the marketers ofNimesulide argued that the manufacturers of 6
    • Candid TalkAN INTERVIEW WITH MR. MANISH up with government organizations that can help bring these tests to the common man at subsidized rates.PUNGALIYA Q.4. What is the current share of pharmacogenomics in Pharmacogenomics can the Indian diagnostic industry? And what is your be described as the study forecast for the next 5 years for this industry? of the effects of genetic The current share of pharmacogenomics in the variation on the efficacy diagnostics industry is somewhere around 5-6 %. and toxicity of a particular However, this scenario will definitely change in the futuredrug. Today oncology and pharmacogenomics is a hot as the growth potential is tremendous and the Indiantopic in the current diagnostics market. In order to molecular diagnostics market is expected to cross US$ 3understand this association, the interview team spoke billion by 2015. In keeping with the proportion of thewith Mr. Manish Pungaliya, Director, Ayugen pharmacagenomics market share, there will be anBiosciences. Ayugen is one of the few companies exceptional growth in this sector too.currently working in the field of pharmacogenomicstesting. Q.5. What are the current as well as the untapped opportunities in cancer pharmacogenomics?Q.1. “Pharmacogenomics, a powerful tool to enhance There is a host of other tests that are available that cancancer treatment”. What are your views on this be developed to check the side effects and efficacy of astatement? drug in a patient’s body based on drug metabolism andPharmcogenomics is drawing attention towards itself in site of action. Also there are other genomics tests whichoncology because most of the new drugs to treat it are try and understand the gene and protein expression inbased on targeted therapies i.e. they target a particular the patient’s body once the drug has been administered.pathway or a gene in a pathway or a protein. Therefore,most of these drugs will only work based on a particular Q.6. What factors should a new entrant take intogenetic profile of the tumour. Pharmacogenomics can account before stepping into this field?guide practitioners through its genetic profiling tests as A new entrant must keep in mind that they should bewell as about which medication will work in a patient and ready with a full fledged marketing plan and a properwhich won’t work. implementation plan to create awareness among the practitioners. Another factor for consideration is to tryQ.2. Even though pharmacogenomics plays a vital role in and bring the cost down from the current levels. Thecancer treatment, do you think it is being utilised major aspect to be worked upon is the awareness levelsefficiently in India as compared to western countries? If in the market since it’s a new field in India. Initially thenot so, what do you think are the probable reasons for investment would be high but the returns on investmentits underutilisation? will certainly follow. Therefore any new entrant mustPharmacogenomics is not being utilized to its full have enough patience to fuel this industry.potential in our country because most of the doctorsdon’t know about the tests and their usage. They are not Compiled by: The PUMBA Gazette Interview Teamaware about the benefits and the power of these testsand even if the doctors are aware of the test they don’tknow how to apply them. But the bright side is that moreand more pharmaceutical companies are pushing the useof these tests with their drugs, thus the awareness andusage will increase rapidly in the future. There is also acost factor involved in the successful application of thistechnique and currently it’s a barrier to the acceptance ofthis form of therapy.Q.3. What steps can be taken to get PharmacogenomicsDiagnostics for cancer treatment within the reach of thecommon man?In the future the cost of the test will automatically comedown as the volume of patients increase, which is boundto happen, considering the utility of these tests. Apartfrom this best way to get the costs down would be to tie 7
    • The PUMBA NewsDHRUV ‘11 were adjudged as the best artists through a poll conducted during the event. Thus, another event wasDHRUV ’11, one of the most awaited cultural events was successfully organized by Alumni cell, the heart ofheld from 17th -19thJan 2011. This year the theme for PUMBA.DHRUV was “AQUATICA.” This event gives the students,from leading B-Schools, an opportunity to present theirmanagerial, cultural & sports skills to come out and NATIONAL SEMINAR 2011perform in front of all & compete with others. More than National seminar 2011, a National level seminar, was5000 participants registered their names for various held on 29th January, 2011 at Le Meridian, Pune. Thisevents. The Grand Finale was held on 19th Jan 2011 at year, the topic of discussion was ‘India on the horizon –‘Alpabachat Bhavan’ which comprised of the finals for The dawn of a global era’. Dr. Santosh Bhave, Vice‘dance competition’ and ‘fashion show’. The chief guest President - HR, Bharat Forge Ltd. graced the event as thefor the Grand Finale was Mr. Nandkishor Kapote, the Chief guest and Dr. R.K. Shevgaonkar, Hon. Vicerenowed Kathak dancer and disciple of Pandit Birju Chancellor, UoP, as the Guest of Honour along with Dr.Maharaj. The judges for the evening were Abhilasha (Capt.) C.M. Chitale, the Head of Department ofMahant Choudhary, Director ‘Nach India’ and Vikram , Management Sciences (PUMBA). The curtain raiserChoreographer from Jhalak Dikhla Ja.’ The event movie, based on the theme, was an apt introduction ofconcluded with overall prize distribution and tallying of the current Indian scenario. There were three panelpoints won in various competitions. The General discussions in the seminar with the topics being India’sChampionship rolling Trophy is given on the basis of Global Footprint - How far have we reached?,collective ranking in each individual event of DHRUV. For Infrastructure Jeopardized- Why can’t we walk the talk?the third consecutive year the trophy for DHRUV’11 was and Globalization and National Commitment-Can theywon by Indira Institute Of Management, Pune. go hand in hand?. The panelists included Mr. Rajesh Ghonasgi, CFO, Persistent Systems Ltd., Mr. DiniarNOSTALGIA 2011 Patel, Editor-Supplement, Times Of India, Mr. Unnikrishnan Menon, AGM - Exports, IPCA Labs, Dr. P CNostalgia`11, An Odyssey to Remember is an annual Nambiar, Director - EXIM, Serum Institute of India, Mr. PAlumni meet & was held on 22nd January, 2011 at the Srinivasan, Global Business Head, Chemical Division,PUMBA campus. This event is a casual gathering of Thermax Ltd., and members of Faculty of PUMBA. Thealumni & is meant for recapturing the past memories of seminar was concluded with a valedictory speech by Dr.PUMBA. It’s an attempt to strengthen the relation Ashok Joshi, Dean, Faculty of Management, University ofbetween PUMBA and its alumni. This year the event Pune. With this seminar, the Seminar cell has indeedrevolved around the theme of ‘Journey’. Deviating from added another feather in its cap!the usual on-stage program, the PUMBA campus wasconverted into a fete with various games organized bythe students. These were enjoyed by the alumni and the YUKTIfun atmosphere pepped up the interactions. “Yukti” a business plan competition was organized by the ED Cell at PUMBA campus on 25th January, 2011. The event consisted of two segments. In the first segment, “BIZZolution”, candidates were given 100 seconds to present their business ideas. The second segment, “BIZZplanmania”, only shortlisted candidates presented their complete business plan. Students from leading B – Schools like JBIMS, N.L. Dalmia, K.J. Somaiya, MIT, Sinhgad Institute participated in these events. Reputed Industrial personalities were invited to judge the business plan competition. Vishwas Kale (Vijayesh Industries) and K.J. Bhumkar (Ex-CMD, Bank of Maharashtra) were the esteemed judges.The Event was inaugurated by Dr. Capt. C.M. Chitale,Professor and Head of Department, PUMBA. The alumni, Compiled by: Nazaneen Saify (MBA BT Sem IV)who have helped PUMBA in the past year, were Mehraj Deshmukh and Nikhil Bhalerao (MBA BT Sem II)honoured as Star Alumni. Also, PUMBA Art Exhibition,wherein the paintings, sketches and photographs by thestudents were displayed, was appreciated. Prof.Aniruddha Joshi along with Abhimanyu Tadwalkar ofMBA BT 2nd year & Bhushan Astulkar MBA- BT 1st year, 8